Summary
June 2007, Vol. 16, No. 6, Pages 829-841 , DOI 10.1517/13543784.16.6.829

Novel pharmacotherapy for fibromyalgia

Patrick B Wood1, Andrew J Holman2 & Kim D Jones3
1Louisiana State University Health Sciences Center – Shreveport, Departments of Family Medicine, Anesthesiology & Psychiatry, 1501 Kings Highway, Shreveport, LA 71130, USA.
2University of Washington, Clinical Rheumatologist, Pacific Rheumatology Associates, 4300 Talbot Road South, Suite 101Renton, Washington 98055, USA
3Oregon Health & Science University, Schools of Nursing and Medicine, 3455 SW US Veterans Road, SNORD, Portland, OR 97239-2941, USA
Author for correspondence



Fibromyalgia is a common disorder that is characterized by chronic widespread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic subgroups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.

Full Text | PDF (221 KB) | PDF Plus (377 KB)

Forward Links to Citing Articles

Abouch V. Krymchantowski, Juline Bryson, Richard B. Lipton, Marcelo E. Bigal. (2008) Neuromodulators for the treatment of headache disorders and fibromyalgia. Current Pain and Headache Reports 12:5, 333-337
Online publication date: 1-Nov-2008.
CrossRef
Jacob N Ablin, Dan Buskila. (2008) Emerging therapies for fibromyalgia. Expert Opinion on Emerging Drugs 13:1, 53-62
Online publication date: 1-Mar-2008.
Summary | Full Text | PDF (140 KB) | PDF Plus (274 KB) 
Luca Scascighini, Haiko Sprott. (2008) Chronic nonmalignant pain: a challenge for patients and clinicians. Nature Clinical Practice Rheumatology 4:2, 74-81
Online publication date: 1-Mar-2008.
CrossRef

Users who read this article also read:

Emerging therapies for fibromyalgia
Jacob N Ablin, Dan Buskila
Expert Opinion on Emerging Drugs, Mar 2008, Vol. 13, No. 1, Pages 53-62.
Summary | Full Text | PDF (140 KB) | PDF Plus (274 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (221 KB)
View PDF Plus (377 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Patrick B Wood
Andrew J Holman
Kim D Jones
Keywords:
central sensitization
chronic widespread pain
descending inhibition
dopamine
fibromyalgia